72 results about "Anticancer treatment" patented technology

The present invention relates to a modified mitochondrial comprising, on the outer membrane of the mitochondrial, an antibody that binds to a cancer cell-specific protein and a cytosine deaminase. It is proved that when the mitochondria and 5-FC are jointly used for treating a pancreatic cancer cell line, the cytotoxicity induced by 5-FC treatment is remarkably enhanced. The effect is proved as follows: 5-FC is converted into 5-FU by cytosine deaminase expressed on a mitochondrial outer membrane, so that pancreatic cancer cells are induced to generate apoptosis. Therefore, the modified mitochondria according to the present invention can be effectively used in anticancer therapy using 5-FC as an anticancer agent.

A combination for use in treating cancer is provided. The combination comprises a therapeutically effective amount of an inhibitor of nuclear import protein Karyopherin Beta 1 (Kpnβ1) such as the substituted pyrrolo[2,3-b]quinoxalines of Formula I and a therapeutically effective amount of an inhibitor of nuclear export protein Chromosome Maintenance 1 (Crm1) such as the hydrazide- containing compounds of Formula II. The combination therapy provides an enhanced anti-cancer therapeutic effect compared to the effect of each of the nuclear transport inhibitors administered alone.

Disclosed herein are methods for treating cancer with inhibitors of FN14 (e.g., Compound 1), or pharmaceutically acceptable salts thereof. The disclosure further provides methods of treating cancer with inhibitors of FN14 or pharmaceutically acceptable salts thereof, in combination with additional anti-cancer therapeutics (e.g., a kinase inhibitor).

A tumor-targeting protein or a fragment thereof, an antibody binding thereto and a use thereof are disclosed. A vector containing a nucleic acid coding for protein A56 or a fragment thereof, and a use thereof are disclosed. An antibody binding to protein A56 or a fragment thereof, and a use thereof are disclosed. The vector containing A56-encoding nucleic acid, a fragment thereof or a mutant thereof uses an oncolytic virus as the vector, and thus, when administered in an individual, specifically kills only cancer cells, primarily. In addition, cancer cells which have survived even after being infected with the oncolytic virus express the protein A56 on the cell surfaces thereof, and thus may be targeted for secondary anticancer therapy employing protein A56-encoding nucleic acid or protein A56 or a fragment thereof, or an antibody binding to A56.

Disclosed herein are programmable bacteria for tumor-targeted immunotherapeutic delivery. In certain embodiments, the programmable bacteria comprise at least one synchronized lysis circuit contained in a single operon which are capable of being further engineered to cyclically produce anti-cancer therapeutic agents including but not limited to nanobodies against immune checkpoint inhibitors and over-expressed markers in cancers, toxins, tumor antigens, cytokines, and chemokines. In some embodiments, the programmable bacteria comprise at least one synchronized lysis circuit contained in a single operon and at least one plasmid producing a therapeutic agent, i.e., at least one plasmid comprising a nucleic acid sequence which encodes a therapeutic agent. The disclosure also provides methods of curing and treating cancer using the programmable bacteria.

The present invention relates to a composition for the prevention or treatment of metastatic cancer, capable of inducing an abscopal effect, which is a systemic anticancer effect, in combination with radiotherapy to treat metastatic cancer that has spread from a primary cancer, wherein, by having confirmed that, upon radiotherapy in which a primary cancer site was irradiated with a low dose of radiation, the abscopal effect, which is a systemic anticancer effect, did not appear, whereas, when type 1 interferon was administered in combination with low-dose radiation to the primary cancer site, an anticancer effect appears even in non-radiated metastatic cancer sites, a composition comprising type 1 interferon is provided as a therapeutic agent or adjuvant for the treatment of metastatic cancer, which induces a systemic anticancer effect upon low-dose radiotherapy.

The present disclosure provides methods and compositions for treating cancer (e.g., lung cancer) in a subject by increasing the expression of PDZ-LIM domain containing protein 2 (PDLIM2) in the subject, or a functional fragment thereof. The present disclosure further provides methods of using PDLIM2 as a marker for determining and monitoring a subject's responsiveness to an anti-cancer treatment, providing a prognosis about a cancer in a subject, and selecting an effective anti-cancer treatment for a subject. The present disclosure also provides in vitro methods of screening anti-cancer agents by assessing whether the expression of PDLIM2 is restored by an anti-cancer agent in a cancer cell.

The invention belongs to the technical field of biological medicines, and particularly relates to a furo-quinoline dictamnine derivative as well as a preparation method and application thereof. The compound is novel and stable in structure, has a remarkable anti-cancer effect, particularly has a relatively high inhibition rate on NCI-H460 and 786-O tumor cells, has relatively low IC50, has a remarkable anti-tumor cell effect, and has a relatively good application prospect in the aspect of anti-cancer treatment. Besides, the preparation method of the furo-quinoline dictamnine derivative has the advantages of wide substrate application range, good functional group compatibility, mild reaction conditions, simplicity and convenience in operation and the like, can be used for large-scale industrial production, and has wide application value in the aspect of developing anti-cancer drugs.

The description discloses selective and potent CDK 4 / 6 inhibitors that exhibit advantageous inhibition of cancer growth, even at low concentrations. One class of CDK 4 / 6 inhibitors refers to substituted pyrrolopyrimidine compounds having a fatty acid moiety and specifically derived from Palbociclib of the general formula [2A], where R1 is hydrogen, aryl, alkyl, alkoxy, cycloalkyl, or heterocyclyl; R2 is hydrogen, halogen, alkyl, acyl, cycloalkyl, alkoxy, alkoxyalkyl, haloalkyl, hydroxyalkyl, alkenyl, alkynyl, nitrile, or nitro; R3 is hydrogen, halogen, alkyl, haloalkyl, hydroxyalkyl, or cycloalkyl; yn is an integer from 9 to 20. These compounds can be used as pharmaceutical compounds for anticancer therapies and are useful for the treatment, prevention and / or improvement of cancer.

The present invention relates to a method of assessing or monitoring the response of a patient suffering from cancer after receiving an anti-cancer treatment, said method being based on the detection of biomarkers. The invention also relates to a kit for carrying out said method and to a method for treating said patient.

The invention relates to two kinds of siRNA (small interfering Ribonucleic Acid) targeting heterogeneous ribonucleoprotein C, wherein the siRNA comprises si-Hnrnpc-1 and si-Hnrnpc-2. Compared with the prior art, the siRNA disclosed by the invention has the advantages that the mRNA accessibility, space occupying factors and gene functional regions are considered, the probability of miss of family and cross-family miss can be reduced, Hnrnpc expression can be effectively reduced, meanwhile, the siRNA has clear targeting and biological effects, and the siRNA has important research value and application prospect for future cancer mechanisms and anti-cancer treatment.

An anticancer agent is provided comprising, as active ingredients, NK cells and a fusion protein comprising an IL-2 protein and a CD80 protein. In one specific formulation, a fusion protein comprising a CD80 fragment, an immunoglobulin Fc region, and an IL-2 variant can activate immune cells such as natural killer cells. Furthermore, since the pharmaceutical composition can effectively inhibit cancer, when co-administered with natural killer cells, it increases immune activity in the body, making it effective for cancer treatment and thus highly applicable to industry.

To provide novel therapeutic compounds that target and inhibit a mitochondrial function, and may serve as anti-cancer therapeutics.SOLUTION: Alkyl-triphenylphosphonium compounds having a saturated, linear alkyl chain of about 9 to about 18 carbons may be used as therapeutic agents to treat cancer. Demonstrative compound dodecyl-TPP (d-TPP) dose-dependently inhibits the propagation of breast cancer stem cells and targets the bulk of the adherent of cancer cells, by decreasing MCF-7 cell viability. Further, d-TPP potently inhibits a mitochondrial oxygen consumption rate, while simultaneously shifting cell metabolism toward a glycolytic pathway. This shift to a strict metabolic dependency on glycolysis may be used to eradicate the residual glycolytic CSC population, by using additional metabolic stressors. For example, d-TPP may be combined with a glycolytic inhibitor or an OXPHOS inhibitor, through co-administration or sequential administration, to treat cancer and eradicate CSCs.SELECTED DRAWING: Figure 2

The present invention relates to a method for developing personalized targeted anticancer therapy based on aptamers and systemically modeling individuals in a microfluidic device. In one embodiment, the present invention provides a method for developing targeted therapy comprising maintaining targeted cancer cells in co-culture with non-target non-cancer cells using a microfluidic device modularly arranged within a closed system to develop aptamers. In another embodiment, the present invention provides a method for developing targeted therapy comprising maintaining target cells in co-culture with non-target cells using a microfluidic device modularly arranged in a closed system. In this regard, the present invention provides development of aptamers for relevant targets that are in homeostatic balance with fluidic components modulated by co-culture with non-target cells.

The invention provides an indole compound as well as a preparation method and application thereof. The structural formula of the compound is shown as a formula (I), a formula (II) or a formula (III). The compound provided by the invention is used as an ATP (adenosine triphosphate) competitive sphingosine kinase 1 (SphK1) or 2 (SphK2) inhibitor, and shows strong enzyme inhibition activity and an effect of resisting tumor cell proliferation. Experiments prove that the indole compound provided by the invention has the potential to be developed into an anti-tumor therapeutic drug and an anti-pulmonary arterial hypertension therapeutic drug, and a new direction is provided for the field of anti-cancer therapeutic drugs. The preparation method of the compound is simple, low in cost, free of dangerous reagents and suitable for industrial production.

The present disclosure provides CDK2 inhibitor compounds that can have a fused 6-6 bicyclic core, such as a naphthyridine, quinazoline, pyridopyrimidine or related isosteric core structure that is further substituted. Also provided herein are pharmaceutical compositions including the subject CDK2 inhibitor compounds, and methods for using compositions of the disclosure as anticancer therapeutics.

This invention provides a compound having the following structure: ( I ) wherein the compound is used for anti-cancer treatments. The invention also provides an assay for selecting one or more compounds that inhibit interaction between ID2 protein and the tumor suppressor complex CRLVHL.

Single-domain antibodies that bind receptor tyrosine kinase (ROR1) are described. The single-domain antibodies can be used for multiple purposes including in research, imaging, diagnosis, and treatment of ROR1-related conditions. The disclosed single-domain antibodies can be used as anti-cancer therapeutics such as antibody-drug conjugates, multi-domain binding molecules, or recombinant receptors or can be used as cancer imaging / diagnostic agents.

The present invention relates to a pharmaceutical composition for preventing or treating cancer, the pharmaceutical composition comprising inflammatory macrophages. Inflammatory macrophages according to an aspect have cancer prevention or treatment effects, such as significantly reducing the size of a tumor while increasing the proportion of inflammatory macrophages, such as M1-type macrophages, in the tumor. In addition, when the pharmaceutical composition is administered in combination with an anticancer drug or further includes the anticancer drug, remarkable cancer prevention or treatment effects are exhibited, even if a relatively small amount of the anticancer drug is included, compared to when each substance is used alone, and side effects of the anticancer drug are not exhibited. Therefore, the pharmaceutical composition according to an aspect can be used in various industrial fields as a monotherapy or combination therapy against cancer.

The present invention relates to a double-stranded RNA having an innate immune response-inducing effect, and a use thereof, and, more specifically, to: a double-stranded RNA comprising a nucleotide into which an innate immune activation motif and a chemical modification are introduced; a composition comprising the double-stranded RNA for enhancing innate immunity; and a pharmaceutical composition comprising the double-stranded RNA.

The invention provides methods of screening a subject for a proliferative disease risk factor which comprises detecting the presence or absence of target cells. The presence of target cells in the subject indicates the subject is at increased risk of developing a proliferative disease or recurrence of a previously treated proliferative disease and defines a new patient subgroup susceptible for treatment with selected anti-proliferative compounds. Methods of screening compounds for the treatment of proliferative diseases based on the presence of target cells and the expression of certain biomarkers by said target cells are also disclosed, along with appropriate compounds and their use in methods of treating such diseases.

The present invention relates to a FLT3L–flagellin hybrid adjuvant with enhanced antigen cross-presentation efficacy and a vaccine composition comprising same. The hybrid adjuvant of the present invention demonstrated significant therapeutic efficacy as an adjuvant for a therapeutic cancer vaccine in a preclinical mouse model of cervical cancer, resulting in complete tumor regression and sustained protection. In addition, the hybrid adjuvant of the present invention induced tumor-specific antigen CD8+ T cell responses and progenitor-exhausted CD8+ T cells (Tpex) due to an increase in cross-presentation by conventional type 1 dendritic cells (cDC1) in tumor-draining lymph nodes and the tumor microenvironment, and the combination of TCV having the hybrid adjuvant applied thereto and anti-PD-1 therapy significantly improves survival outcomes in anti-PD-1–resistant tumors, and thus can be advantageously applied in anticancer immunotherapy using therapeutic cancer vaccines.

The invention relates to the technical field of disease diagnosis, and provides a specific biomarker for granulomatous mastitis and a preparation method and application thereof, the specific biomarker is nicotinamide phosphoribosyltransferase truncated protein, and the amino acid sequence of the specific biomarker is shown as SEQ ID NO. 1. The NAMPT truncated protein is a specific molecule directly related to the GM pathogenesis. The detection result has high directivity, the positive result supports GM diagnosis, and the negative result is helpful for eliminating the GM diagnosis, so that non-iconography objective evidence is provided for differential diagnosis. GM and breast cancer are clearly distinguished in the early stage of diagnosis, and unnecessary anti-cancer treatment or delay of the real illness state is avoided.

The present disclosure provides compositions and methods of modulating the response of a subject to an anti-cancer treatment, comprising fecal-derived extracellular vesicles, filtrates or compositions comprising the same, which can be administered with an anti-cancer treatment. The composition disclosed herein can be substantially free of living biological material present in the human colon and biological material less than about 5-10 kDa molecular weight.

The invention discloses siRNA of targeted knockdown CBLC gene and application of the siRNA in preparation of medicines for treating cancers, and belongs to the field of biological medicines. The invention provides siRNA (small interfering Ribonucleic Acid) of a targeted CBLC gene, the sequence of a positive-sense strand of the siRNA is shown as SEQ ID NO.1, and the sequence of an antisense strand of the siRNA is shown as SEQ ID NO.2. The siRNA is injected into a pancreatic cancer mouse tumor, and the tumor size and the CBLC gene expression quantity are detected. Experimental results show that compared with control group mice injected with normal saline, the tumor growth speed of the mice injected with siRNA is remarkably slowed down, the tumor volume and weight are remarkably reduced, and the CBLC gene expression quantity is remarkably reduced; the siRNA provided by the invention can effectively inhibit the development of pancreatic cancer by knocking down the CBLC gene. The invention provides a theoretical basis for molecular mechanism research of CBLC and an anti-cancer treatment strategy of pancreatic cancer.

Provided is a combination comprising a compound of formula (A), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof, as a POLQ inhibitor, and at least one anti-cancer therapeutic agent or radiation therapy for use in the prevention or treatment of cancer, as well as the use of the combination in the prevention or treatment of cancer. The structure of the compound of the formula (A) is shown in the specification.

The present invention relates to a pharmaceutical composition for preventing or treating cancer, and preparation method therefor, the composition comprising a complex of a transdermal permeation peptide and a saccharide, and a lectin. It has been identified that, when the composition comprising the complex of the transdermal permeation peptide and the saccharide, and the lectin is used for cancer treatment, skin permeation of anticancer substances is improved, anti-tumor activity and anti-metastasis properties are exhibited, and hepatotoxicity is not exhibited, and thus effective use as a composition for anticancer treatment is possible.